Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy
Status:
Unknown status
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The type 1 diabetes patients who were still normoalbuminuric and normotensive, after 17 years
duration and a second research kidney biopsy, could enter the double blind treatment study of
Atacand or Placebo.
The treatment study continues for five years treatment and ends with a third kidney biopsy.
The study hypothesis is that the effect of ARB during 5 years on the histopathology are more
pronounced than the effect on histopathology of placebo.